Olema Pharmaceuticals Analyst Ratings
Olema Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/11/2023 | 119.61% | HC Wainwright & Co. | → $28 | Reiterates | Buy → Buy |
| 09/15/2023 | 49.02% | JP Morgan | $16 → $19 | Maintains | Overweight |
| 09/06/2023 | 64.71% | Oppenheimer | → $21 | Reiterates | Outperform → Outperform |
| 09/05/2023 | 119.61% | HC Wainwright & Co. | $22 → $28 | Maintains | Buy |
| 08/10/2023 | 25.49% | JP Morgan | $14 → $16 | Maintains | Overweight |
| 08/09/2023 | 41.18% | Credit Suisse | $16 → $18 | Maintains | Outperform |
| 08/09/2023 | 72.55% | HC Wainwright & Co. | $17 → $22 | Maintains | Buy |
| 07/21/2023 | 64.71% | Oppenheimer | → $21 | Initiates Coverage On | → Outperform |
| 05/11/2023 | 33.33% | HC Wainwright & Co. | $14 → $17 | Maintains | Buy |
| 03/10/2023 | -13.73% | Credit Suisse | $12 → $11 | Maintains | Outperform |
| 03/10/2023 | 17.65% | HC Wainwright & Co. | $12 → $15 | Maintains | Buy |
| 02/22/2023 | -5.88% | Credit Suisse | → $12 | Initiates Coverage On | → Outperform |
| 07/06/2022 | 25.49% | Canaccord Genuity | → $16 | Assumes | → Buy |
| 06/10/2022 | — | HC Wainwright & Co. | Upgrades | Neutral → Buy | |
| 02/28/2022 | — | HC Wainwright & Co. | Initiates Coverage On | → Neutral | |
| 12/14/2020 | 370.59% | Canaccord Genuity | → $60 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月11日 | 119.61% | HC Wainwright公司 | →$28 | 重申 | 购买→购买 |
| 2023/09/15 | 49.02% | 摩根大通 | $16→$19 | 维护 | 超重 |
| 09/06/2023 | 64.71% | 奥本海默 | →$21 | 重申 | 跑赢→跑赢大盘 |
| 09/05/2023 | 119.61% | HC Wainwright公司 | $22→$28 | 维护 | 买 |
| 2023年08月10日 | 25.49% | 摩根大通 | $14→$16 | 维护 | 超重 |
| 08/09/2023 | 41.18% | 瑞士信贷 | $16→$18 | 维护 | 跑赢大盘 |
| 08/09/2023 | 72.55% | HC Wainwright公司 | $17→$22 | 维护 | 买 |
| 07/21/2023 | 64.71% | 奥本海默 | →$21 | 开始承保 | →跑赢大盘 |
| 2023年05月11日 | 33.33% | HC Wainwright公司 | $14→$17 | 维护 | 买 |
| 03/10/2023 | -13.73% | 瑞士信贷 | $12→$11 | 维护 | 跑赢大盘 |
| 03/10/2023 | 17.65% | HC Wainwright公司 | $12→$15 | 维护 | 买 |
| 02/22/2023 | -5.88% | 瑞士信贷 | →$12 | 开始承保 | →跑赢大盘 |
| 07/06/2022 | 25.49% | 卡纳科特·格纳奇 | →$16 | 假设 | →购买 |
| 2022/10/06 | - | HC Wainwright公司 | 升级 | 中性→购买 | |
| 02/28/2022 | - | HC Wainwright公司 | 开始承保 | →中性 | |
| 12/14/2020 | 370.59% | 卡纳科特·格纳奇 | →$60 | 开始承保 | →购买 |
What is the target price for Olema Pharmaceuticals (OLMA)?
奥莱马制药公司(OLMA)的目标价是多少？
The latest price target for Olema Pharmaceuticals (NASDAQ: OLMA) was reported by HC Wainwright & Co. on October 11, 2023. The analyst firm set a price target for $28.00 expecting OLMA to rise to within 12 months (a possible 119.61% upside). 12 analyst firms have reported ratings in the last year.
奥莱马制药公司(纳斯达克代码：OLMA)的最新目标价是由HC Wainwright&Co.于2023年10月11日报道的。这家分析公司将目标价定为28美元，预计OLMA将在12个月内上涨至(可能上涨119.61%)。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Olema Pharmaceuticals (OLMA)?
奥莱马制药公司(OLMA)的最新分析师评级是多少？
The latest analyst rating for Olema Pharmaceuticals (NASDAQ: OLMA) was provided by HC Wainwright & Co., and Olema Pharmaceuticals reiterated their buy rating.
分析师对奥莱马制药公司(纳斯达克代码：OLMA)的最新评级由HC Wainwright&Co.提供，奥莱马制药公司重申其买入评级。
When is the next analyst rating going to be posted or updated for Olema Pharmaceuticals (OLMA)?
奥莱马制药(OLMA)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Olema Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Olema Pharmaceuticals was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Olema制药公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Olema制药的上一次评级是在2023年10月11日提交的，所以你应该预计下一次评级将在2024年10月11日左右的某个时候提供。
Is the Analyst Rating Olema Pharmaceuticals (OLMA) correct?
分析师对奥莱马制药(OLMA)的评级正确吗？
While ratings are subjective and will change, the latest Olema Pharmaceuticals (OLMA) rating was a reiterated with a price target of $0.00 to $28.00. The current price Olema Pharmaceuticals (OLMA) is trading at is $12.75, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的奥莱马制药(OLMA)评级被重申，目标价在0.00美元至28.00美元之间。奥莱马制药公司(Olema PharmPharmticals)目前的交易价格为12.75美元，在分析师的预测范围内。